Nucleic acids and proteins from Streptococcus groups A and B

Patent metadata

Field	Value
Publication number	US-9840538-B2
Application number	US-201514751790-A
Country	US
Kind code	B2
Filing date	Jun 26, 2015
Priority date	Oct 27, 2000
Publication date	Dec 12, 2017
Grant date	Dec 12, 2017

Abstract

The invention provides proteins from group B streptococcus ( Streptococcus agalactiae ) and group A streptococcus ( Streptococcus pyogenes ), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

First claim

The invention claimed is:

1. An isolated nucleic acid molecule comprising a sequence selected from the group consisting of: (a) a sequence encoding a polypeptide comprising SEQ ID NO: 4212, and having at least one nucleotide modification to SEQ ID NO: 4211; and (b) a sequence encoding a fusion polypeptide, said fusion polypeptide comprising (i) a polypeptide which has at least 95% sequence identity to SEQ ID NO: 4212 and (ii) a heterologous polypeptide sequence.

2. The isolated nucleic acid molecule of claim 1 , comprising the nucleic acid sequence encoding the fusion polypeptide, said fusion polypeptide comprising (i) the polypeptide which has at least 95% sequence identity to SEQ ID NO: 4212 and (ii) the heterologous polypeptide sequence.

3. The isolated nucleic acid molecule of claim 1 , comprising the nucleic acid sequence encoding the fusion polypeptide, said fusion polypeptide comprising (i) the polypeptide which has at least 99% sequence identity to SEQ ID NO: 4212 and (ii) the heterologous polypeptide sequence.

4. The isolated nucleic acid molecule of claim 1 , comprising the nucleic acid sequence encoding the fusion polypeptide, said fusion polypeptide comprising (i) SEQ ID NO: 4212 and (ii) the heterologous polypeptide sequence.

5. An isolated nucleic acid molecule comprising a sequence that is fully complementary to the sequence of claim 1 .

6. An isolated a vector comprising a heterologous nucleic acid sequence and:
a) the nucleic acid sequence of claim 1 ;
b) the nucleic acid sequence of SEQ ID NO: 4211;
c) a nucleic acid sequence encoding a polypeptide comprising SEQ ID NO: 4212; or
d) a nucleic acid sequence encoding the polypeptide comprising SEQ ID NO: 4212, and having 95% or greater sequence identity to SEQ ID NO: 4211.

7. The isolated vector of claim 6 , wherein the heterologous nucleic acid sequence comprises a promoter operably linked to said nucleic acid sequence.

8. An isolated host cell comprising the isolated nucleic acid molecule of claim 1 .

9. The isolated host cell of claim 8 , wherein the cell is a mammalian cell, a bacterial cell other than a Streptococcus pyogenes cell or a Streptococcus agalactiae cell, or an Escherichia coli cell.

10. A composition comprising: (a) the isolated nucleic acid molecule of claim 1 , an isolated vector comprising said nucleic acid sequence, an isolated host cell comprising said isolated nucleic acid molecule or said vector, a polypeptide encoded by said nucleic acid sequence, or an isolated cell comprising said polypeptide, and (b) a pharmaceutically acceptable vehicle.

11. The composition of claim 10 , further comprising a polycationic agent and/or wherein the component of (a) is encapsulated in a lipid or packaged in a liposome.

12. An isolated host cell comprising the isolated vector of claim 6 .

13. The isolated host cell of claim 12 , wherein the cell is a mammalian cell, a bacterial cell other than a Streptococcus pyogenes cell or a Streptococcus agalactiae cell, or an Escherichia coli cell.

14. A composition comprising: (a) the isolated vector of claim 6 or an isolated host cell comprising said vector, and (b) a pharmaceutically acceptable vehicle.

15. The composition of claim 14 , further comprising a polycationic agent and/or wherein the component of (a) is encapsulated in a lipid or packaged in a liposome.

16. The isolated nucleic acid molecule of claim 1 , comprising the sequence encoding the polypeptide comprising SEQ ID NO: 4212, and having at least one nucleotide modification to SEQ ID NO: 4211.

17. The isolated nucleic acid molecule of claim 16 , comprising the sequence encoding the polypeptide comprising SEQ ID NO: 4212, and having at least 99% sequence identity to the sequence of SEQ ID NO: 4211.

18. The isolated vector of claim 6 , comprising the nucleic acid sequence of claim 1 .

19. The isolated vector of claim 6 , comprising the nucleic acid sequence of SEQ ID NO: 4211.

20. The isolated vector of claim 6 , comprising the nucleic acid sequence encoding the polypeptide comprising SEQ ID NO: 4212.

21. The isolated vector of claim 6 , comprising the nucleic acid sequence encoding the polypeptide of SEQ ID NO: 4212, and having 95% or greater sequence identity to SEQ ID NO: 4211.

22. The isolated vector of claim 21 , wherein the heterologous nucleic acid sequence comprises a promoter operably linked to said nucleic acid sequence.

23. An isolated host cell comprising the isolated vector of claim 21 .

24. An isolated host cell comprising the isolated vector of claim 20 .

Assignees

• Novartis Ag
• J Craig Venter Inst Inc

Inventors

• Telford John
• Masignani Vega
• Scarselli Maria
• Grandi Guido
• Tettelin Herve
• Fraser Claire

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P27/16

  Otologicals · CPC title